ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...
Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...
Atacicept met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from ...
The Punch on MSN
FMDQ celebrates innovation, resilience in financial markets
FMDQ Group Plc has commemorated the 8th edition of its prestigious GOLD Awards, continuing its long-standing tradition of ...
Statistically significant and clinically meaningful improvements in mean ACQ-5 scores were reported at week 16 versus placebo ...
Secondary analyses of the ESSENCE trial were presented at the American Association for the Study of Liver Diseases (AASLD), ...
Sydnexis Announces Topline Pivotal Data from Phase 3 STAR Trial of SYD-101 for Patients with Pediatric Progressive Myopia Presented at AMCP Nexus 2025 ...
Detailed price information for Amarin Corp ADR (AMRN-Q) from The Globe and Mail including charting and trades.
Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- ...
In a second poster, spatial computational histology relying on baseline fibrosis features was used to predict response to denifanstat ...
Efficacy and safety of subcutaneous self-administered gefurulimab in generalized myasthenia gravis: topline results from a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback